Astellas Pharma, Inc. (ALPMF) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $15.20. The rating moved from Neutral to Oversold on August 19, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$15.20
• Last changeMoved from Neutral to Oversold on August 19, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - General

See all oversold Healthcare stocks →

AI analysis

Astellas exhibits a steady commercial base and a pipeline that can deliver episodic catalysts, while exposure to biologics and specialty medicines offers medium-term growth avenues. Near-term market conditions are muted and sector themes are mixed — supportive activity for CRO/CDMO demand contrasts with payer margin pressure. Financial flexibility and potential M&A optionality support resilience, but regulatory, competitive, and patent risks create meaningful outcome variability over the next several quarters.

Key factors

• Diversified commercial portfolio with steady cash flow from established products
• Late-stage pipeline and partnerships that can deliver intermittent upside (regulatory approvals or label expansions)
• Exposure to biologics and specialty therapies aligns with ongoing demand in diagnostics, CRO/CDMO activity
• Prudent balance-sheet profile relative to large-cap peers supports R&D and potential bolt-on M&A
• Stable macro backdrop and muted market flow in the short window reduce volatility risk in near term
• M&A multiples in biotech/pharma remain elevated, making strategic dispositions or acquisitions feasible for value creation

Risks

• Regulatory setbacks or trial failures for key pipeline assets could materially impact growth expectations
• Pricing pressure from payers and increased competition in key therapeutic areas could compress margins
• Patent expirations or generic competition on core products would reduce revenues
• Foreign exchange volatility given multinational operations could weigh reported results
• Execution risk on manufacturing, supply-chain disruptions, or quality issues that affect product availability
• Macroeconomic deterioration or rapid risk-off environment could reduce investor appetite for cyclical pharma moves

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.